Invesco Ltd. Sc Pharmaceuticals Inc. Transaction History

Invesco Ltd.

$600 Billion
Q3 2025

A detailed history of Invesco Ltd. transactions in Sc Pharmaceuticals Inc. stock. As of the latest transaction made, Invesco Ltd. holds 24,167 shares of SCPH stock, worth $137,026. This represents 0.0% of its overall portfolio holdings.

Number of Shares

24,167

Previous 25,879 6.62%

Holding current value

$137,026

Previous $98,000 38.78%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$3.86 - $5.84 $6,608 - $9,998	-1,712 Reduced 6.62%	24,167 $136,000
Q2 2025 Aug 13, 2025	SELL	$2.02 - $4.27 $5,702 - $12,054	-2,823 Reduced 9.84%	25,879 $98,000
Q1 2025 May 12, 2025	BUY	$2.63 - $3.68 $2,861 - $4,003	1,088 Added 3.94%	28,702 $75,000
Q4 2024 Feb 13, 2025	BUY	$3.14 - $4.53 $19,069 - $27,510	6,073 Added 28.19%	27,614 $97,000
Q3 2024 Nov 12, 2024	SELL	$4.12 - $5.51 $4,602 - $6,154	-1,117 Reduced 4.93%	21,541 $98,000

Q2 2024 Aug 13, 2024	BUY	$3.51 - $5.21 $34,942 - $51,865	9,955 Added 78.37%	22,658 $98,000
Q1 2024 May 14, 2024	SELL	$4.86 - $6.39 $349 - $460	-72 Reduced 0.56%	12,703 $63,000
Q4 2023 Feb 12, 2024	SELL	$4.7 - $6.63 $69,414 - $97,918	-14,769 Reduced 53.62%	12,775 $80,000
Q3 2023 Nov 13, 2023	BUY	$7.0 - $9.82 $89,600 - $125,696	12,800 Added 86.81%	27,544 $196,000
Q2 2023 Aug 11, 2023	BUY	$8.94 - $11.74 $131,811 - $173,094	14,744 New	14,744 $150,000
Q2 2021 Aug 17, 2021	SELL	$5.19 - $7.38 $55,667 - $79,157	-10,726 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$5.65 - $7.66 $1,090 - $1,478	193 Added 1.83%	10,726 $71,000
Q4 2020 Feb 16, 2021	BUY	$5.17 - $9.41 $54,455 - $99,115	10,533 New	10,533 $56,000

Others Institutions Holding SCPH

# of Institutions

117

Shares Held

38.3M

Call Options Held

835K

Put Options Held

173K

View Full List

About scPharmaceuticals Inc.

Ticker SCPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,402,100
Market Cap $155M
Description
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product p...

More about SCPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account